Ruti Aga: Six Years, One Forged Prescription and the Clinic That Never Existed

There was a half marathon in China that March morning. Ruti Aga won it. What surfaced months later was not the win — it was a sample, and behind the sample, a piece of paper. The Athletics Integrity Unit statement issued on Thursday carried two sanctions standing separately: two years for the presence of methylprednisolone, four years for tampering. Add them. Six years, from 10 September.

The real document is the prescription. Aga cited a knee injury as the reason for the treatment. The prescription was written by a family member with no medical registration, who said in response that he had used "an old prescription pad from a former workplace." The clinic whose name was printed on that pad told the AIU investigation, plainly, that it had nothing to do with it. I went looking for the clinic. I found an old pad its own hospital was disowning.

Aga is not an unknown name. She won the 2026 Tokyo Marathon. Three second-place finishes at World Marathon Majors. Berlin 2026 in 2:18:34 — that figure sits in my notebook, source verification still pending, so I am keeping it in the estimate column and not the fact column. I watched the Tokyo 2026 race at three in the morning from a one-bedroom in Jersey City, on a screen, with no press box anywhere near me. What showed that morning was tempo — thirty quiet kilometres, then arithmetic in the last ten. In a marathon I trust splits, not commentary.

Now the March race. The source gives no name, no date, no year. What it gives: a half marathon in China, won, and an in-competition test that came back positive. A half marathon has no Olympic qualifying function. So the question is why that race matters. The answer sits in the same place as the money and the testing. For East African marathoners, China's label-race circuit is the income between Majors — appearance fee, few races, low risk, no championship pressure. For the AIU, that same circuit is the highest-yield testing ground it has. Two economies are colliding in the same race. A road race's testing window opens at 23:59 the night before, which means an injection given days earlier still gets caught.

First fact, and much of the coverage got it wrong: methylprednisolone is not an anabolic steroid. It is a glucocorticoid, WADA Prohibited List class S9, and it is prohibited in-competition only — by injection, oral or rectal route. The reporting called it a "steroid," and that one word filed the whole case into a box it does not belong in. It matters, because intra-articular methylprednisolone for knee synovitis is routine sports medicine in distance runners. Out of competition it is entirely legal. It becomes a violation only when residues are present in competition. Which means a defence existed — route, timing, and a real medical record. The forged prescription destroyed precisely the defence that could have worked.

The sanction ledger is straightforward: two years for presence, four for tampering. The arithmetic tells us the panel refused the no-significant-fault mitigation — two years on presence means a Specified Substance finding without proven intent, but without relief either. Four years on tampering is the Code's standard. The interesting part is that a forged document is itself circumstantial evidence of concealment intent, yet it did not escalate the presence sanction. The panel kept the two accounts separate. Backdating to 10 September is a procedural benefit, not a discount — provisional suspension time is deducted, and the athlete gains nothing real.

What the source does not say also needs to be on the record. It does not state whether the March result and its prize money will be annulled. Standard AIU practice voids the result of the competition where the sample was collected, plus ranking points accrued after it. I am writing that as unconfirmed, not as fact. The age arithmetic is clear: 32, a six-year ban, a return at 38. Ethiopian women's marathon depth is such that a 2:18 performer is not automatically selectable. On paper the ban is six years; by career arithmetic it is lifetime.

The root cause is the knee, not the prescription. Chronic knee pathology is a known load-bearing failure mode in high-volume marathoners, and the pressure to mask pain is tied to appearance-fee income. The cheapest tool for that is a glucocorticoid. The medical network around her is kinship-based, not document-based. No TUE, no team physician, no washout protocol. Three things were missing, and one prescription pad took the place of all three. The tampering charge rests partly on an interview, not a document alone; language and translation conditions in AIU interviews with Ethiopian athletes have been a recurring objection, and it is on the record here, unresolved.

Six years for a substance with no proven endurance benefit will be quoted from both directions: as proof of AIU rigour, and as proof of inconsistent enforcement against African road runners. Both readings are easy. Both are incomplete. What gets missed is this: the case is not about the substance, it is about document verification. The enforcement frontier is shifting from detection to paperwork. Aga is not an outlier — she belongs to a recognizable family of cases where the first violation is the substance and the second, heavier one is the explanation. And the question nobody is asking: who advised her? An agent or manager will have seen or accepted that document. The AIU statement names only the family member. Whether the agent was investigated is unanswered. An athlete with a lawyer frequently has no team doctor; and an athlete with no team doctor frequently has a relative who can produce a pad.

Aga remains the 2026 Tokyo champion. No sanction erases that record, absent a separate finding of earlier use — and the source mentions no such finding. A CAS appeal window is open, typically about 21 days from the reasoned decision, though a document-based finding is hard to overturn. The question is what the next 32-year-old with a knee injection and no team doctor will have available to her. Until that question is answered, pads will keep being produced — and keep being caught.